Enveda raises $311 million to advance nature-derived AI drugs in clinical trialsMachine translation
Biotech startup Enveda has raised $311 million in a Series E round at a $2 billion valuation. It uses AI to seek drugs from plants and microbes and is testing several candidates in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.
Enveda raises $311 million to advance nature-derived AI drugs in clinical trials
Biotech startup Enveda has raised $311 million in a Series E round at a $2 billion valuation. It uses AI to seek drugs from plants and microbes and is testing several candidates in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.
材料 11c9d5df22434038a7436f4f57b95121；建议 d13808f5918a4cebb8a8e4471caad505；系统证据核验通过，非人工审稿。
Read at the original source